Therapeutic cancer vaccines: Why so few randomised phase III studies reflect the initial optimism of phase II studies

Vaccine

Volumn 29, Issue 47, 2011, Pages 8501-8505

  Dalgleish, Angus G ^a  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Cancer vaccines; Inflammation; Need for biomarkers; Patient selection; Phase 2 trials; Phase 3 trials

Indexed keywords

ACETYLSALICYLIC ACID; CANCER VACCINE; CANVAXIN; CYCLOPHOSPHAMIDE; GANGLIOSIDE GM2; GEMCITABINE; LENALIDOMIDE; MYCOBACTERIUM VACCINE; PNEUMOCOCCUS VACCINE; SRL 172; UNCLASSIFIED DRUG;

CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; HUMAN; LUNG NON SMALL CELL CANCER; MELANOMA; MYCOBACTERIUM VACCAE; NEOPLASM; PATIENT CARE; PATIENT SELECTION; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT FAILURE;

CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; HUMANS; NEOPLASMS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 82455172010     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.09.012     Document Type: Review

References (41)

1. Copier J., Dalgleish A. Overview of Cancer Vaccines 2009, Wiley-VCH Verlag GmbH & Co, Weinheim.
2. Dalgleish A., Pandha H. Tumor antigens as surrogate markers and targets for therapy and vaccines. Adv Cancer Res 2007, 96:175-190.
3. Higano C.S., Schellhammer P.F., Small E.J., Burch P.A., Nemunaitis J., Yuh L., et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer 2009, 115(16):3670-3679.
4. Jocham D., Richter A., Hoffmann L., Iwig K., Fahlenkamp D., Zakrzewski G., et al. Adjuvant autologous renal tumour cell vaccine and risk of tumour progression in patients with renal-cell carcinoma after radical nephrectomy: phase III, randomised controlled trial. Lancet 2004, 363(9409):594-599.
5. Uyl-de Groot C.A., Vermorken J.B., Hanna M.G., Verboom P., Groot M.T., Bonsel G.J., et al. Immunotherapy with autologous tumor cell-BCG vaccine in patients with colon cancer: a prospective study of medical and economic benefits. Vaccine 2005, 23(17-18):2379-2387.
6. Livingston P.O., Ritter G., Srivastava P., Padavan M., Calves M.J., Oettgen H.F., et al. Characterization of IgG and IgM antibodies induced in melanoma patients by immunization with purified GM2 ganglioside. Cancer Res 1989, 49(24 Pt 1):7045-7050.
7. Livingston P.O., Wong G.Y., Adluri S., Tao Y., Padavan M., Parente R., et al. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J Clin Oncol 1994, 12(5):1036-1044.
8. Chapman P.B., Morrissey D.M., Panageas K.S., Hamilton W.B., Zhan C., Destro A.N., et al. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin+QS21 vaccine: a dose-response study. Clin Cancer Res 2000, 6(3):874-879.
9. Helling F., Zhang S., Shang A., Adluri S., Calves M., Koganty R., et al. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21. Cancer Res 1995, 55(13):2783-2788.
10. Eggermont A., Suchiu S., Ruka W., Marsden J., Testori A., Corrie P., et al. EORTC 18961: post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd Interim analysis led to an early disclosure of the results. J Clin Oncol 2008, 26(May Suppl.). [abstract 9004].
11. Grange J.M., Krone B., Stanford J.L. Immunotherapy for malignant melanoma-tracing Ariadne's thread through the labyrinth. Eur J Cancer 2009, 45(13):2266-2273.
12. Hrouda D., Baban B., Dunsmuir W.D., Kirby R.S., Dalgleish A.G. Immunotherapy of advanced prostate cancer: a phase I/II trial using Mycobacterium vaccae (SRL172). Br J Urol 1998, 82(4):568-573.
13. Maraveyas A., Baban B., Kennard D., Rook G.A., Westby M., Grange J.M., et al. Possible improved survival of patients with stage IV AJCC melanoma receiving SRL 172 immunotherapy: correlation with induction of increased levels of intracellular interleukin-2 in peripheral blood lymphocytes. Ann Oncol 1999, 10(7):817-824.
14. Nicholson S., Guile K., John J., Clarke I.A., Diffley J., Donnellan P., et al. A randomized phase II trial of SRL172 (Mycobacterium vaccae) +/- low-dose interleukin-2 in the treatment of metastatic malignant melanoma. Melanoma Res 2003, 13(4):389-393.
15. O'Brien M.E., Saini A., Smith I.E., Webb A., Gregory K., Mendes R., et al. A randomized phase II study of SRL172 (Mycobacterium vaccae) combined with chemotherapy in patients with advanced inoperable non-small-cell lung cancer and mesothelioma. Br J Cancer 2000, 83(7):853-857.
16. Assersohn L., Souberbielle B.E., O'Brien M.E., Archer C.D., Mendes R., Bass R., et al. A randomized pilot study of SRL172 (Mycobacterium vaccae) in patients with small cell lung cancer (SCLC) treated with chemotherapy. Clin Oncol (R Coll Radiol) 2002, 14(1):23-27.
17. O'Brien M.E., Anderson H., Kaukel E., O'Byrne K., Pawlicki M., Von Pawel J., et al. SRL172 (killed Mycobacterium vaccae) in addition to standard chemotherapy improves quality of life without affecting survival, in patients with advanced non-small-cell lung cancer: phase III results. Ann Oncol 2004, 15(6):906-914.
18. Stanford J.L., Stanford C.A., O'Brien M.E., Grange J.M. Successful immunotherapy with Mycobacterium vaccae in the treatment of adenocarcinoma of the lung. Eur J Cancer 2008, 44(2):224-227.
19. von Reyn C.F., Mtei L., Arbeit R.D., Waddell R., Cole B., Mackenzie T., et al. Prevention of tuberculosis in Bacille Calmette-Guerin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine. AIDS 2010, 24(5):675-685.
20. Morton D.L., Foshag L.J., Hoon D.S., Nizze J.A., Famatiga E., Wanek L.A., et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992, 216(4):463-482.
21. Morton D.L., Hsueh E.C., Essner R., Foshag L.J., O'Day S.J., Bilchik A., et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 2002, 236(4):438-448. discussion 48-9.
22. Hsueh E.C., Essner R., Foshag L.J., Ollila D.W., Gammon G., O'Day S.J., et al. Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine. J Clin Oncol 2002, 20(23):4549-4554.
23. Hsueh E.C., Famatiga E., Shu S., Ye X., Morton D.L. Peripheral blood CD4+ T-cell response before postoperative active immunotherapy correlates with clinical outcome in metastatic melanoma. Ann Surg Oncol 2004, 11(10):892-899.
24. Hsueh E.C., Gupta R.K., Qi K., Morton D.L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998, 16(9):2913-2920.
25. Hsueh E.C., Morton D.L. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin Cancer Biol 2003, 13(6):401-407.
26. Weber J.S., O'Day S., Urba W., Powderly J., Nichol G., Yellin M., et al. Phase I/II study of ipilimumab for patients with metastatic melanoma. J Clin Oncol 2008, 26(36):5950-5956.
27. Morton D.L., Mozzillo N., thompson J.F., Kelley M.C., Faries M.B., Wagner J., et al. An international, randomized, phase III trial of bacillus Calmette-Guerin (BCG) plus allogeneic melanoma vaccine (MCV) or placebo after complete resection of melanoma metastatic to regional or distant sites. J Clin Oncol (Meet Abstr) 2007, 25(18 Suppl. 8508).
28. Michael A., Ball G., Quatan N., Wushishi F., Russell N., Whelan J., et al. Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables. Clin Cancer Res 2005, 11(12):4469-4478.
29. O'Byrne K.J., Dalgleish A.G. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001, 85(4):473-483.
30. Acres B., Quoix E., Ramlau R., Lacoste G., Bastien B.M., Tavernaro A., et al. Biomarkers associated with clinical outcome in advanced non-small cell lung cancer patients treated with TG4010. J Clin Oncol 2009, 27(15).
31. Derhovanessian E., Adams V., Hahnel K., Groeger A., Pandha H., Ward S., et al. Pretreatment frequency of circulating IL-17+ CD4+ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. Int J Cancer 2009, 125(6):1372-1379.
32. Chiarella P., Vulcano M., Bruzzo J., Vermeulen M., Vanzulli S., Maglioco A., et al. Anti-inflammatory pretreatment enables an efficient dendritic cell-based immunotherapy against established tumors. Cancer Immunol Immunother 2008, 57(5):701-718.
33. Newton-Bishop J.A., Beswick S., Randerson-Moor J., Chang Y.M., Affleck P., Elliott F., et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol 2009, 27(32):5439-5444.
34. Grimes D.S. Vitamin D and cholesterol: the importance of the sun 2009, Tennison Pub., Great Britain.
35. Bartlett J.B., Dredge K., Dalgleish A.G. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004, 4(4):314-322.
36. Galustian C., Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opin Pharmacother 2009, 10(1):125-133.
37. Bartlett J.B., Michael A., Clarke I.A., Dredge K., Nicholson S., Kristeleit H., et al. Phase 1 study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer 2004, 90:955-961.
38. Dredge K., Marriott J.B., Todryk S.M., Muller G.W., Chen R., Stirling D.I., et al. Protective antitumor immunity induced by a costimulatory thalidomide analog in conjunction with whole tumor cell vaccination is mediated by increased Th1-type immunity. J Immunol 2002, 168(10):4914-4919.
39. Noonan K.A., Ferguson A., Huff C.A., Emerling A., Mgebroff S., Wilson R., et al. The immunomodulatory role of lenalidomide on prevnar (R) responses in patients with relapsed multiple myeloma: a comprehensive analysis of the immune response. Blood 2008, 112(11):956.
40. Eisen T., Trefzer U., Hamilton A., Hersey P., Millward M., Knight R.D., et al. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 2010, 116(January (1)):146-154.
41. Stebbing J, Dalgleish A, Gifford-Moore A, Martin A, Gleeson C, Wilson G, et al., An intra-patient placebo-controlled phase I trial to evaluate the safety and tolerability of intradermal IMM-101 in melanoma. Ann Oncol 2011; published online sept 19.